[{"data":1,"prerenderedAt":65},["ShallowReactive",2],{"q-nurse-108-2-basic-medicine-035":3},{"subject":4,"subjectSlug":5,"subjectFullName":6,"question":7,"related":34,"lastmod":64},"基礎醫學","basic-medicine","基礎醫學(包括解剖學、生理學、病理學、藥理學、微生物學與免疫學)",{"id":8,"webId":9,"year":10,"session":11,"subject":4,"number":12,"stem":13,"options":14,"answer":19,"answerNote":20,"images":21,"explanation":22,"explanationDeep":23,"topics":24,"freq":11},"nurse-108-2-基礎醫學-035","nurse-108-2-basic-medicine-035",108,2,35,"人類免疫不全病毒（HIV）進入 T 細胞需要何種分子當作病毒的高親和力受體？",{"A":15,"B":16,"C":17,"D":18},"CD3","CD4","CD5","CD10","B",null,[],"本題考點在HIV進入宿主細胞的受體辨識。依病毒學，HIV外套膜醣蛋白gp120與宿主T細胞表面的CD4分子高親和力結合，這是病毒附著的第一步，故選B。CD4為輔助型T細胞（helper T cell）的標記，這也解釋HIV為何專一破壞CD4陽性T細胞、造成免疫低下。A的CD3為T細胞受體複合物的訊息傳遞分子，非HIV受體。C的CD5、D的CD10分別為某些淋巴球次群與前驅B細胞、淋巴瘤的標記，皆非HIV結合對象。","HIV入侵為兩步驟：gp120先結合主要受體CD4，構型改變後再結合輔受體CCR5或CXCR4，最後gp41介導膜融合。CCR5-Δ32突變者對HIV有部分抗性，是治療研究焦點。臨床監測即以CD4計數評估免疫狀態（\u003C200\u002FµL進入愛滋病期）。記憶口訣：CD4是門把、CCR5\u002FCXCR4是門鎖，兩者都對上病毒才進得去。可連結：gp120\u002Fgp41、CCR5輔受體、CD4計數分期、輔助型T細胞。",[25,27,30,32],{"term":26,"count":11},"輔助型T細胞",{"term":28,"count":29},"HIV受體CD4",1,{"term":31,"count":29},"gp120醣蛋白",{"term":33,"count":29},"CCR5輔受體",[35,39,44,48,53,58],{"webId":36,"stem":37,"number":38,"year":10,"session":11},"nurse-108-2-basic-medicine-036","岡氏複合體（Ghon complex）是那一類結核病的病理表現？",36,{"webId":40,"stem":41,"number":42,"year":43,"session":29},"nurse-109-1-basic-medicine-052","下列何種藥物可抑制 tumor tyrosine kinase 活性，因而可用於 chronic myeloid leukemia 及 gastrointestinal stromal tumor？",52,109,{"webId":45,"stem":46,"number":47,"year":43,"session":11},"nurse-109-2-basic-medicine-066","下列何者是神經毒素？",66,{"webId":49,"stem":50,"number":51,"year":52,"session":29},"nurse-111-1-basic-medicine-024","下列有關微血管及組織液交換的敘述，何者錯誤？",24,111,{"webId":54,"stem":55,"number":56,"year":57,"session":11},"nurse-112-2-basic-medicine-048","下列病毒感染與其所引起疾病之配對關係，何者錯誤？",48,112,{"webId":59,"stem":60,"number":61,"year":62,"session":63},"nurse-113-3-basic-medicine-042","下列那一種補體分子促進肥大細胞（mast cell）分化效果最佳？",42,113,3,"2026-09-04",1788510705097]